Donawa Lifescience President, Maria E. Donawa, M.D., has been interviewed by Amanda Maxwell of MEDTECH INSIGHT on the subject of European medical device guidance document MDCG 2024-3 concerning clinical investigation plans in the journal dated 8 April 2024. The guidance, full title ‘Guidance on the content of the clinical investigation plan for clinical investigations of…
Donawa Lifescience President, Maria E. Donawa, M.D., has authored a ‘Regulatory Recap’ article on LinkedIn titled ‘CEPs: Parameters vs outcome parameters, what’s the difference?’ The topic arises because of confusion among manufacturers, notified bodies, and competent authorities regarding the interpretation of certain requirements of the EU Medical Device Regulation (MDR, 2017/745) for clinical evaluation plans…
The European Commission has recently published its annual report on devices subject to the clinical evaluation consultation procedure (CECP), available from here. Titled ‘Commission Staff Working Document: Annual overview of devices subject to the clinical evaluation consultation procedure pursuant to Article 54(4) of Regulation (EU) 2017/745 on medical devices (July 2022-June 2023)’, the report identifies…
MDCG has published its updated schedule for MDR/IVDR guidance documents, revealing that more than 50 are scheduled to be released before the end of 2024. Copies are available from this web address.
The International Medical Device Regulators Forum (IMDRF) has now released the ‘Outcome Statement’ from its latest meeting, held 11-15 March 2024 in Washington DC, USA. Copies of the report are available from here, which include a note of the decisions made by the ‘regulators only’ closed session, during which eight revised guidance documents were approved…
The 8th EAAR Annual Conference on New Medical Device Regulations (RMD2024) took place in Brussels, Belgium, on 26-27 February 2024, featuring speakers from across the MedTech industry, including regulators and notified bodies. Organized by the European Association of Authorised Representatives (EAAR), the conference served as an inclusive platform for all stakeholders across the both medical…
The US Food and Drug Administration (FDA) has outlined a standardized approach for collecting and reporting on race and ethnicity data in clinical trials and studies in a new draft guidance document. “Using standardized terminology for race and ethnicity helps ensure that data are collected and reporting consistently in submission to FDA,” the agency wrote…
At the MDCG Subgroup on Standards (WG 2) held on 19 January 2024, it was confirmed that for all industrial sectors, the accepted symbol for ‘Authorised Representative’ would change from ‘EC¦REP’ to ‘EU¦REP’. It has been proposed that a two-year transition period would be allowed for product labeling to be brought into line with the…
Misuse of medical devices at home is the most pressing health technology safety hazard, nonprofit patient safety organization ECRI reports. ECRI’s list of the top 10 safety hazards related to medical technology also includes concerns about AI and data security. Since 2008, ECRI has issued its list of the top 10 safety hazards related to…
The US Food and Drug Administration (FDA) has published its long-awaited Quality Management System Regulation (QMSR) final rule that harmonizes its requirements with the International Organization for Standardization (ISO) standard ISO 13485. The agency said the rule will ensure consistency in regulatory expectations for device makers across regulatory regimes, while saving industry hundreds of millions…
